PDCD1 and Miyoshi myopathy: Lenalidomide in combination with PD-1/PD-L1-blocking antibodies blocks bone marrow stroma cell-induced MM growth through induction of interferon-γ (IFN-γ) and granzyme-B in T and NK cells, as well as inhibiting MDSC-mediated immune suppression.